Global Bioabsorbable Vascular Scaffold Market Strategic Research Report

The global bioabsorbable vascular scaffold (BVS) market occupies a distinctive position at the intersection of interventional cardiology and advanced biomaterials science. Unlike conventional metallic drug-eluting stents, BVS platforms are engineered to provide temporary mechanical support to a diseased coronary artery and then dissolve completely, restoring vessel vasomotion and eliminating the long-term risks associated with a permanent implant. Valued at approximately USD 320 million in 2024, the market is shaped by a sustained global burden of coronary artery disease, which accounts for more than 9 million deaths annually worldwide, and by the persistent clinical aspiration to move beyond a permanent metallic cage paradigm in percutaneous coronary intervention. As second-generation scaffolds with thinner struts and refined polymer chemistries progress through regulatory pipelines in the United States, Europe, and Asia, commercial expectations for the segment are being recalibrated following the discontinuation of Abbott's first-generation Absorb BVS in 2017—an episode that tempered but did not extinguish institutional investment in the category.

Growth in this market is being driven by three converging forces. First, the clinical unmet need in younger coronary artery disease patients—those under 60 years of age who face decades of potential implant-related complications—creates a compelling value proposition for a fully dissolving scaffold that metal stents structurally cannot address. Trials such as ABSORB III and subsequent next-generation studies have provided increasingly granular data on the relationship between strut thickness, endothelialization kinetics, and late scaffold thrombosis, enabling device engineers at companies including Biotronik, Elixir Medical, and Kyoto Medical Planning to deliver geometrically optimized designs. Second, the proliferation of advanced imaging modalities, particularly optical coherence tomography and intravascular ultrasound, is improving implantation technique standardization, directly reducing the procedural errors that contributed to adverse outcomes with early-generation devices. A meaningful restraint, however, remains the lingering physician hesitancy rooted in the Absorb experience, combined with reimbursement uncertainty in key payer markets including the United States and Germany, which prolongs adoption cycles and raises the cost of commercial entry for pipeline entrants.

This report delivers a structured, evidence-based analysis of the global BVS market covering the 2025–2032 forecast period, with historical context extending to 2019. It segments the market by scaffold material type, polymer backbone, and clinical application, and provides country-level granularity across the six most commercially significant geographies. Corporate strategy teams evaluating entry or expansion decisions, investment analysts modeling pipeline-stage asset valuations, M&A advisors conducting sector due diligence, and procurement managers assessing hospital formulary strategies will find this report an essential commercial reference.